Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures | Zendy

Alexandra U. Scherrer | Zendy; Viktor von Wyl | Zendy; Christof A Fux | Zendy; Milos Opravil | Zendy; Heiner C. Bucher | Zendy; Aurélie Fayet | Zendy; Laurent A. Décosterd | Zendy; B Hirschel | Zendy; B. Khanlari | Zendy; Sabine Yerly | Zendy; Thomas Klimkait | Zendy; Hansjakob Furrer | Zendy; Bruno Ledergerber | Zendy; Huldrych F. Günthard | Zendy

Open Access

Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures

Author(s) -

Alexandra U. Scherrer,

Viktor von Wyl,

Christof A Fux,

Milos Opravil,

Heiner C. Bucher,

Aurélie Fayet,

Laurent A. Décosterd,

B Hirschel,

B. Khanlari,

Sabine Yerly,

Thomas Klimkait,

Hansjakob Furrer,

Bruno Ledergerber,

Huldrych F. Günthard

Publication year - 2010

Publication title -

jaids journal of acquired immune deficiency syndromes

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.162

H-Index - 157

eISSN - 1944-7884

pISSN - 1525-4135

DOI - 10.1097/qai.0b013e3181bca4ec

Subject(s) - raltegravir , medicine , enfuvirtide , viral load , odds ratio , regimen , confidence interval , clinical trial , randomized controlled trial , logistic regression , maraviroc , ritonavir , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , antigen , gp41 , epitope

Raltegravir (RAL) achieved remarkable virologic suppression rates in randomized-clinical trials, but today efficacy data and factors for treatment failures in a routine clinical care setting are limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research